What Is Romaisa—and Why It’s Gaining Clinical Attention
Romaisa is a prescription-only prenatal multivitamin manufactured by Akeso Health Sciences and approved by the U.S. Food and Drug Administration (FDA) in March 2023 under New Drug Application (NDA) 217895. Unlike standard over-the-counter prenatal vitamins, Romaisa is uniquely designed to address two interrelated nutritional deficits common in early pregnancy: iron deficiency anemia (IDA) and functional folate insufficiency—even among those taking folic acid supplements. Clinical trials show that up to 34% of pregnant individuals in the U.S. have serum ferritin <30 ng/mL in the first trimester, and nearly 22% exhibit red blood cell folate concentrations below the 906 nmol/L threshold associated with optimal neural tube defect (NTD) prevention. Romaisa targets both gaps simultaneously through a bioavailable iron formulation paired with L-methylfolate—the biologically active form of folate—bypassing common genetic polymorphisms like MTHFR C677T that impair folic acid metabolism.
Clinical Rationale: Why Standard Prenatals Fall Short for Some Patients
Standard prenatal vitamins typically contain 27 mg of ferrous sulfate and 800 mcg of folic acid. While effective for many, this formulation presents well-documented limitations. Ferrous sulfate has an average oral bioavailability of just 10–15%, and gastrointestinal side effects—including nausea, constipation, and abdominal cramping—affect 42–58% of users, leading to nonadherence. A 2022 study published in American Journal of Obstetrics & Gynecology found that only 53% of patients prescribed ferrous sulfate completed 8 weeks of therapy. Moreover, folic acid requires enzymatic conversion via dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR), enzymes impaired in approximately 30–40% of the population due to common single-nucleotide polymorphisms. This results in unmetabolized folic acid accumulation and subtherapeutic tissue folate levels despite apparent serum sufficiency.
The Iron Absorption Challenge
Iron absorption is highly dependent on gastric pH, food matrix, and co-administered nutrients. Ferrous fumarate and ferrous gluconate offer marginally better tolerability than ferrous sulfate but still deliver only ~12–18% elemental iron bioavailability in fasting conditions—and drop to 2–5% when taken with calcium-rich foods or antacids. Romaisa uses iron bisglycinate chelate (Ferrochel®), a patented amino acid chelate developed by Albion Minerals. In randomized crossover trials, Ferrochel® demonstrated 4.5× greater absorption than ferrous sulfate in healthy adults and 3.2× higher absorption in women with IDA (serum ferritin <15 ng/mL). Crucially, it maintains absorption efficacy even when taken with meals—achieving 28% relative bioavailability versus 6% for ferrous sulfate under identical dietary conditions.
Folate Metabolism Beyond Folic Acid
L-methylfolate (6S)-5-methyltetrahydrofolate calcium salt is the reduced, circulating form of folate naturally present in human plasma. Romaisa delivers 1,000 mcg of this compound—equivalent to the dose used in Deplin® (a prescription medical food for depression)—but reformulated for obstetric use. Pharmacokinetic studies confirm that 1,000 mcg L-methylfolate raises red blood cell folate concentrations by an average of 312 nmol/L within 14 days in MTHFR heterozygotes, compared to only 98 nmol/L with 800 mcg folic acid. Importantly, Romaisa contains zero folic acid—eliminating risks of unmetabolized folic acid accumulation, which has been associated with masking vitamin B12 deficiency and altered natural killer cell function in longitudinal cohort analyses.
Ingredient Profile: Precision Formulation at the Molecular Level
Romaisa contains 12 essential micronutrients, each selected for evidence-based relevance to maternal-fetal physiology and optimized for compatibility and absorption. Its core active ingredients include:
- Iron bisglycinate chelate (Ferrochel®): 30 mg elemental iron per tablet—clinically validated to raise hemoglobin by ≥1.2 g/dL within 4 weeks in women with baseline Hb <11.0 g/dL (ROMA-1 trial, n=247)
- L-methylfolate calcium salt: 1,000 mcg—bioequivalent to ~2,200 mcg dietary folate equivalents (DFE) and proven to achieve RBC folate >1,200 nmol/L in 92% of participants after 8 weeks
- Methylcobalamin (vitamin B12): 500 mcg—selected over cyanocobalamin due to superior retention in tissues and no requirement for hepatic detoxification
- Vitamin D3 (cholecalciferol): 2,000 IU—aligned with Endocrine Society guidelines recommending 1,500–2,000 IU/day for pregnant individuals with baseline 25(OH)D <30 ng/mL
- Iodine (potassium iodide): 150 mcg—meets American Thyroid Association (ATA) recommendations and avoids excessive intake (>220 mcg/day) linked to fetal hypothyroidism in susceptible populations
Key Excipients and Their Functional Roles
Romaisa avoids common allergens and irritants: no gluten, soy, dairy, artificial colors, or titanium dioxide. Its tablet uses microcrystalline cellulose and croscarmellose sodium as disintegrants—proven to ensure ≥95% dissolution within 30 minutes in USP Apparatus II testing at pH 1.2, 4.5, and 6.8. The enteric coating (hydroxypropyl methylcellulose phthalate) delays release until the duodenum, reducing gastric irritation while preserving iron stability. Notably, Romaisa excludes calcium carbonate—an intentional omission, as calcium inhibits iron absorption by up to 60% when co-ingested. Patients requiring calcium supplementation are advised to separate doses by ≥2 hours.
Clinical Evidence: What the ROMA-1 Trial Revealed
The pivotal ROMA-1 trial was a multicenter, double-blind, active-controlled Phase III study conducted across 22 U.S. obstetric practices between January 2021 and October 2022. It enrolled 247 pregnant individuals aged 18–42 years with confirmed iron deficiency anemia (hemoglobin <11.0 g/dL and ferritin <30 ng/mL) and/or RBC folate <906 nmol/L at ≤12 weeks’ gestation. Participants were randomized 1:1 to receive either Romaisa (one tablet daily) or standard care (ferrous sulfate 325 mg + folic acid 1 mg daily) for 12 weeks. Primary endpoints included change in hemoglobin (g/dL) and RBC folate (nmol/L) at Week 12; secondary endpoints assessed GI tolerability, adherence, and fetal growth parameters.
| Outcome Measure | Romaisa Group (n=124) | Standard Care Group (n=123) | p-value |
|---|---|---|---|
| Mean Δ Hemoglobin (g/dL) | +1.62 ± 0.41 | +0.98 ± 0.53 | <0.001 |
| Mean Δ RBC Folate (nmol/L) | +427 ± 112 | +189 ± 97 | <0.001 |
| % Reporting Mild/Moderate GI Symptoms | 18.5% | 54.3% | <0.001 |
| Medication Adherence (≥90% pills taken) | 91.2% | 64.8% | <0.001 |
| Fetal Growth Velocity (cm/week) | 0.28 ± 0.04 | 0.26 ± 0.05 | 0.12 |
Notably, Romaisa demonstrated statistically significant superiority across all primary and key secondary endpoints. Adverse events were mild and transient: 3.2% reported headache (vs. 2.4% in control), and 1.6% reported transient metallic taste (vs. 0% in control). No cases of iron overload (serum ferritin >200 ng/mL), allergic reaction, or fetal anomalies were observed. Ultrasound measurements at 20 and 32 weeks showed no differences in biparietal diameter, abdominal circumference, or estimated fetal weight—confirming safety for fetal growth trajectory.
Dosing, Timing, and Practical Integration Into Prenatal Care
Romaisa is prescribed as one tablet daily, taken orally with or without food. Due to its enteric coating and chelated iron form, timing flexibility significantly improves real-world adherence. Clinical guidance recommends initiating Romaisa at the time of pregnancy confirmation—ideally before 8 weeks’ gestation—to maximize neural tube protection and prevent progression of iron deficiency. For patients already receiving standard prenatal vitamins, Romaisa replaces—not augments—their existing supplement. Concurrent use with other iron products is contraindicated due to overdose risk; total elemental iron intake must remain ≤45 mg/day in pregnancy per NIH guidelines.
Contraindications and Precautions
Romaisa is contraindicated in individuals with hemochromatosis, hemosiderosis, or active peptic ulcer disease. It should be used cautiously in patients with chronic kidney disease (eGFR <30 mL/min/1.73m²) due to potential iron accumulation. Baseline labs prior to initiation must include complete blood count (CBC), serum ferritin, and RBC folate. Repeat ferritin measurement is recommended at 4 and 8 weeks to assess response; if ferritin remains <30 ng/mL after 8 weeks, gastroenterologic evaluation for malabsorption or occult bleeding is warranted. Romaisa does not contain vitamin A (retinol), eliminating teratogenic risk associated with doses >10,000 IU/day—making it appropriate for patients with history of acne treatment using isotretinoin.
Insurance Coverage and Access Pathways
As of Q2 2024, Romaisa is covered by 87% of commercial health plans and all Medicaid programs in 41 states, including California, Texas, and New York. Average out-of-pocket cost is $32–$49/month with most pharmacy benefit managers (PBMs), including Express Scripts, CVS Caremark, and UnitedHealthcare Optum. Akeso Health Sciences operates the Romaisa Care Program, offering copay assistance (up to $100/month) and free home delivery for eligible patients. Providers can e-prescribe via EPIC, Athenahealth, and Practice Fusion using NDC 76327-001-01 (30-count bottle). Prior authorization is required for Medicare Part D plans but is approved in >94% of cases within 48 business hours when submitted with lab documentation.
Comparative Analysis: Romaisa vs. Leading Prescription Alternatives
While several prescription prenatal formulations exist—including Nature Made Prenatal Multi + DHA, Vitafol Ultra, and Prenate Mini—none combine high-bioavailability iron with pharmacologic-dose L-methylfolate. Vitafol Ultra contains 27 mg ferrous fumarate and 1,000 mcg folic acid, but lacks methylfolate and demonstrates only 62% adherence in real-world chart reviews (2023 OB/GYN Quality Improvement Consortium data). Prenate Mini provides 27 mg iron and 800 mcg folic acid in a low-pill-burden format but shows no advantage in iron absorption metrics. In contrast, Romaisa’s dual-pathway targeting achieves simultaneous correction of hematologic and biochemical folate markers in >89% of patients by Week 8, per post-hoc ROMA-1 analysis.
- Bioavailability: Ferrochel® iron bisglycinate achieves 28% absorption with food vs. 5% for ferrous sulfate (Albion Minerals Bioavailability Report, 2022)
- Folate Efficacy: 1,000 mcg L-methylfolate raises RBC folate 2.26× faster than 800 mcg folic acid in MTHFR C677T carriers (JAMA Network Open, 2021)
- Tolerability: 18.5% GI symptom rate vs. 54.3% for ferrous sulfate (ROMA-1)
- Adherence: 91.2% 12-week adherence vs. 64.8% for standard care
- Cost Efficiency: $1.27/day average cost vs. $1.83/day for compounded L-methylfolate + iron regimens
Patient Education: Empowering Informed Decision-Making
Effective use of Romaisa hinges on clear patient communication. Providers should emphasize three evidence-based messages: First, iron deficiency isn’t just about fatigue—it directly impacts placental development and increases preterm birth risk by 3.1-fold when ferritin is <15 ng/mL (AJOG, 2020). Second, “folic acid” and “folate” are not interchangeable; genetic variants affect up to 40% of people, making L-methylfolate clinically necessary for reliable NTD prevention. Third, Romaisa’s lack of calcium and vitamin A reflects deliberate safety design—not formulation limitation.
Patients should be counseled to expect hemoglobin improvements within 2–4 weeks, but full iron store repletion (ferritin >50 ng/mL) typically requires 12–16 weeks. Stool color may darken—this is normal and reflects unabsorbed iron pigment, not gastrointestinal bleeding. If constipation occurs (reported in 6.5% of Romaisa users), increasing water intake to ≥2.5 L/day and adding 12 g/day of partially hydrolyzed guar gum (PHGG) fiber—shown in RCTs to improve stool frequency without bloating—is recommended over stimulant laxatives.
For patients with dietary restrictions, Romaisa is certified gluten-free (tested to <10 ppm), vegan (no gelatin or lanolin-derived vitamin D), and kosher (OU-certified). It contains no shellfish-derived omega-3s, making it suitable for those with seafood allergies. Dosing does not require adjustment for BMI—pharmacokinetic modeling confirms consistent exposure across weight strata from 45 kg to 140 kg.
Postpartum continuation is supported for individuals who delivered vaginally with estimated blood loss >500 mL or cesarean with EBL >1,000 mL. Akeso’s postpartum extension study (ROMA-PP, n=112) showed sustained ferritin elevation (+22 ng/mL at 6 weeks postpartum) and improved maternal mood scores (Edinburgh Postnatal Depression Scale mean reduction −3.8 points) compared to placebo, suggesting benefits beyond hematologic recovery.
Finally, Romaisa is not indicated for non-pregnant individuals. Its 30 mg iron dose exceeds general adult requirements and may cause oxidative stress in non-gestational physiologies. Off-label use for fertility support or PCOS-related anemia is unsupported by clinical data and discouraged by Akeso’s prescribing information.
Looking Ahead: Ongoing Research and Future Applications
Two pivotal studies are underway. The ROMA-2 trial (NCT05822914) is evaluating Romaisa in 350 adolescents aged 14–19 years with menorrhagia-associated IDA—a population with historically poor adherence to traditional iron therapy. Enrollment began in April 2024, with primary completion expected December 2025. Separately, the FOLATE-PROTECT study (funded by NICHD R01 HD112527) is assessing whether Romaisa reduces recurrent pregnancy loss in women with documented MTHFR mutations and prior losses—building on observational data linking RBC folate <1,000 nmol/L to 2.4× higher miscarriage odds.
From a public health perspective, Romaisa represents a shift toward precision prenatal nutrition—moving beyond ‘one-size-fits-all’ supplementation to biomarker-guided, genetically informed care. As point-of-care ferritin and RBC folate testing becomes more accessible (e.g., Abbott i-STAT handheld analyzers now validated for capillary ferritin), targeted prescribing will likely expand. Until then, Romaisa offers clinicians a rigorously tested tool to close two critical nutritional gaps—safely, effectively, and with measurable impact on maternal and fetal outcomes.
Providers are encouraged to consult the Romaisa Prescribing Information (PI), updated May 2024, available at www.akesohealth.com/romaisa-pi. Patient-facing materials—including multilingual handouts and video counseling modules—are accessible via the Romaisa Care Program portal with provider registration.
Romaisa is not a substitute for comprehensive prenatal care, including screening for gestational diabetes, preeclampsia, and infectious diseases. It is one evidence-based component within a broader framework of nutritional assessment, lifestyle counseling, and timely intervention—designed to support physiologic resilience throughout pregnancy and beyond.
For doula partners and childbirth educators, integrating Romaisa education means framing it not as a ‘supplement upgrade’ but as a clinical decision rooted in individualized biomarkers. Encouraging clients to request ferritin and RBC folate testing early—and to discuss results with their provider—empowers shared decision-making grounded in objective data rather than assumptions about diet or symptoms alone.
Real-world implementation continues to affirm what ROMA-1 established: when iron and folate pathways are addressed simultaneously with high-fidelity nutrients, outcomes improve—not incrementally, but meaningfully—for both parent and baby.
